Stockreport

Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first subject has been dosed in a Phase 1 [Read more]